Civilia announces the acquisition of Data Traffic and strengthens its position in the Canadian market

Civilia, a Quebec-based company renowned for its smart mobility technology solutions, announces the acquisition of Compilation Data Traffic, a firm with over 20 years of expertise in multimodal traffic surveys. Civilia is taking a new step forward by combining two complementary areas of expertise to better address mobility issues. On one hand, Civilia's ability to […]

Transat A.T. Responds to Requisition and Sets Meeting Date

Transat A.T. Inc. (“Transat” or the “Corporation”) confirmed today that its board of directors (the “Board”), in response to the formal requisition (the “Requisition”) made by shareholder Financière Outremont Inc. (the “Requisitioning Shareholder”) requesting that the Corporation convene a special meeting of shareholders to vote on certain proposed changes to the Board, has called an

GMG Unveils Graphene Aluminium-Ion Battery That Fully Charges in 6 Minutes

Brisbane, Australia–(Newsfile Corp. – December 15, 2025) – Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) (“GMG” or the “Company“) is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology (“G+AI“) being developed by GMG and the University of Queensland (“UQ“) under a Joint Development Agreement with Rio Tinto, one of

smart #2 Advances Real-World Testing on All-New Electric Compact Architecture

— smart's newECA platform is being validated through rigorous testing. — smart #2 will present a new vision while preservingthe essential DNA of the fortwo. — Progress on-track for world premiere in 2026. The reinvention of smart's iconic city car is accelerating as the all-electric #2 advances through real-world testing of its Electric Compact Architecture

REI Systems Welcomes Eric Olson as Chief Corporate Development Officer

REI Systems, a technology service provider with 35 years of delivering reliable, effective, and innovative solutions that advance government, is pleased to announce the appointment of Eric Olson as Chief Corporate Development Officer (CCDO). In this role, Eric will lead the development and execution of REI's mergers and acquisitions strategy, with a focus on strengthening

FullPAC Announces GOTV Campaign Strategist of the Year

Manny Alvarez Achieved a 77.14% Win Rate for Clients in 2025 Mr. Alvarez's Bilingual Talent Helped Secure Victories for 27 out of 35 Campaign Clients that Implemented GOTV's Voter Turnout Plan FullPAC Currently Intends to List on Nasdaq Under Ticker Symbol “GOTV,” Subject to Nasdaq Approval, to Capitalize on Record-Breaking 2026 Election Spend Limited Number

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

(NASDAQ:CPRX), CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management

FullPAC Announces GOTV Campaign Strategist of the Year

FullPAC Announces GOTV Campaign Strategist of the Year GlobeNewswire December 15, 2025 Manny Alvarez Achieved a 77.14% Win Rate for Clients in 2025 Mr. Alvarez's Bilingual Talent Helped Secure Victories for 27 out of 35 Campaign Clients that Implemented GOTV's Voter Turnout Plan FullPAC Currently Intends to List on Nasdaq Under Ticker Symbol “GOTV,” Subject

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire December 15, 2025 CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced

Dilon Technologies Announces FDA Approval and U.S. Launch of MarginProbe® 2, Next-Generation Intraoperative margin assessment technology

Dilon Technologies, a leading provider of medical devices, has gained FDA approval for its MarginProbe® 2 system and is announcing its launch in the U.S. This is the next-generation device for real-time intraoperative margin assessment in breast cancer surgery. MarginProbe® 2 is designed to help surgeons achieve greater precision during breast-conserving surgeries, reducing the need

Scroll to Top